{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:57:38Z","timestamp":1790909858817,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.ejphar.2012.09.024","type":"journal-article","created":{"date-parts":[[2012,9,26]],"date-time":"2012-09-26T15:34:09Z","timestamp":1348673649000},"page":"194-202","source":"Crossref","is-referenced-by-count":38,"title":["A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations"],"prefix":"10.1016","volume":"696","author":[{"given":"Sayaka","family":"Fukuda-Tsuru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Anabuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2012.09.024_bib1","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1210\/jc.2003-031907","article-title":"Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes","volume":"89","author":"Ahren","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2012.09.024_bib2","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1021\/jm050261p","article-title":"Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes","volume":"48","author":"Augeri","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2012.09.024_bib3","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0021-9150(00)00601-8","article-title":"Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress","volume":"155","author":"Bae","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejphar.2012.09.024_bib4","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1007\/s001250051445","article-title":"Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7\u201336 amide) concentrations and improves oral glucose tolerance in obese Zucker rats","volume":"42","author":"Balkan","year":"1999","journal-title":"Diabetologia"},{"issue":"Suppl 3","key":"10.1016\/j.ejphar.2012.09.024_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1046\/j.1365-2362.32.s3.3.x","article-title":"Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction","volume":"32","author":"Boden","year":"2002","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2012.09.024_bib6","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1124\/jpet.105.087064","article-title":"Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats","volume":"315","author":"Burkey","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2012.09.024_bib7","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1161\/01.CIR.0000027569.76671.A8","article-title":"Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment","volume":"106","author":"Ceriello","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2012.09.024_bib8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2147\/VHRM.S4039","article-title":"Potential of liraglutide in the treatment of patients with type 2 diabetes","volume":"5","author":"Deacon","year":"2009","journal-title":"Vasc. Health Risk Manage."},{"key":"10.1016\/j.ejphar.2012.09.024_bib9","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1517\/13543784.13.9.1091","article-title":"Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes?","volume":"13","author":"Deacon","year":"2004","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.ejphar.2012.09.024_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1517\/13543784.12.1.87","article-title":"Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes","volume":"12","author":"Drucker","year":"2003","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.ejphar.2012.09.024_bib11","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s001250050617","article-title":"Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow-up","volume":"39","author":"Hanefeld","year":"1996","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2012.09.024_bib12","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/diabetes.47.11.1663","article-title":"Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes","volume":"47","author":"Holst","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2012.09.024_bib13","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s00125-009-1611-5","article-title":"The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice","volume":"53","author":"Hsieh","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2012.09.024_bib14","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1248\/bpb.20.354","article-title":"Effect of a new hypoglycemic agent, A-4166 [(\u2212)-N-(trans-4-isopropylcyclohexanecarbonyl)-d-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide","volume":"20","author":"Ikenoue","year":"1997","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejphar.2012.09.024_bib15","first-page":"E500","article-title":"Abnormal oral glucose tolerance in genetically obese (fa\/fa) rats","volume":"248","author":"Ionescu","year":"1985","journal-title":"The Am. J. Physiol."},{"key":"10.1016\/j.ejphar.2012.09.024_bib16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.atherosclerosis.2011.08.012","article-title":"Postprandial lipemia and cardiovascular disease risk: interrelationships between dietary, physiological and genetic determinants","volume":"220","author":"Jackson","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejphar.2012.09.024_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1021\/jm0493156","article-title":"(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes","volume":"48","author":"Kim","year":"2005","journal-title":"J Med. Chem."},{"key":"10.1016\/j.ejphar.2012.09.024_bib18","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","article-title":"Glucagon-like peptide-1 7\u201336: a physiological incretin in man","volume":"2","author":"Kreymann","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2012.09.024_bib19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/713609354","article-title":"Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV","volume":"40","author":"Lambeir","year":"2003","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.ejphar.2012.09.024_bib20","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ejphar.2008.04.047","article-title":"Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys","volume":"589","author":"Lee","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.09.024_bib21","first-page":"297","article-title":"The effect of insulin on lipolysis","volume":"13","author":"Mahler","year":"1964","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2012.09.024_bib22","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1517\/13543780902766802","article-title":"Exenatide once weekly for the treatment of type 2 diabetes","volume":"18","author":"Malone","year":"2009","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.ejphar.2012.09.024_bib23","doi-asserted-by":"crossref","first-page":"6874","DOI":"10.1073\/pnas.120069197","article-title":"Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26","volume":"97","author":"Marguet","year":"2000","journal-title":"Proc. Nat. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2012.09.024_bib24","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00125-006-0340-2","article-title":"Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes","volume":"49","author":"Matikainen","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2012.09.024_bib25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1476-5381.2009.00145.x","article-title":"Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db\/db mice","volume":"157","author":"Moritoh","year":"2009","journal-title":"Brit. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.09.024_bib26","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2337\/db05-1602","article-title":"Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes","volume":"55","author":"Mu","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2012.09.024_bib27","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00125-004-1334-6","article-title":"Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin","volume":"47","author":"Nakagami","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2012.09.024_bib28","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM199306103282306","article-title":"Long-term complications of diabetes mellitus","volume":"328","author":"Nathan","year":"1993","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ejphar.2012.09.024_bib29","first-page":"299","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women"},{"key":"10.1016\/j.ejphar.2012.09.024_bib30","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.2337\/diabetes.50.5.1158","article-title":"Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability","volume":"50","author":"Oakes","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2012.09.024_bib31","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2337\/diabetes.47.8.1253","article-title":"Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide","volume":"47","author":"Pederson","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2012.09.024_bib32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0021-9150(01)00588-3","article-title":"Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the quebec cardiovascular study","volume":"160","author":"Pirro","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejphar.2012.09.024_bib33","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1210\/jc.87.6.2913","article-title":"FFA-induced endothelial dysfunction can be corrected by vitamin C","volume":"87","author":"Pleiner","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2012.09.024_bib34","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1210\/er.2007-0023","article-title":"Glucolipotoxicity: fuel excess and beta-cell dysfunction","volume":"29","author":"Poitout","year":"2008","journal-title":"Endocrine Rev."},{"key":"10.1016\/j.ejphar.2012.09.024_bib35","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2337\/diabetes.52.3.741","article-title":"Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats","volume":"52","author":"Pospisilik","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2012.09.024_bib36","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1185\/030079906X162746","article-title":"Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes","volume":"23","author":"Pratley","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejphar.2012.09.024_bib37","doi-asserted-by":"crossref","first-page":"G943","DOI":"10.1152\/ajpgi.00303.2004","article-title":"GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats.","volume":"288","author":"Qin","year":"2005","journal-title":"Am. J. Physiol. Gastrointest. liver Physiol."},{"key":"10.1016\/j.ejphar.2012.09.024_bib38","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1016\/j.bmc.2006.01.022","article-title":"[(S)-gamma-(arylamino)prolyl]thiazolidine compounds as a novel series of potent and stable DPP-IV inhibitors","volume":"14","author":"Sakashita","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2012.09.024_bib39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejphar.2010.06.001","article-title":"RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes","volume":"652","author":"Singh","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.09.024_bib40","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1001\/jama.1996.03540110036029","article-title":"A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction","volume":"276","author":"Stampfer","year":"1996","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ejphar.2012.09.024_bib41","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2337\/diabetes.51.5.1461","article-title":"Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats","volume":"51","author":"Sudre","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2012.09.024_bib42","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejphar.2003.12.029","article-title":"K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent","volume":"486","author":"Takasaki","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.09.024_bib43","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00125-003-1111-y","article-title":"Diabetic dyslipidaemia: from basic research to clinical practice","volume":"46","author":"Taskinen","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2012.09.024_bib44","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)12131-1","article-title":"Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European diabetes epidemiology group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2012.09.024_bib45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1124\/jpet.107.135723","volume":"325","author":"Thomas","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2012.09.024_bib46","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1463-1326.2011.01362.x","article-title":"Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes","volume":"13","author":"Tremblay","year":"2011","journal-title":"Diabetes, Obes. Metab."},{"key":"10.1016\/j.ejphar.2012.09.024_bib47","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2337\/diabetes.44.8.863","article-title":"Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications","volume":"44","author":"Unger","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2012.09.024_bib48","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.2337\/db07-0136","article-title":"Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes","volume":"56","author":"Vella","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2012.09.024_bib49","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1021\/jm030091l","article-title":"1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties","volume":"46","author":"Villhauer","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2012.09.024_bib50","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1023\/A:1018874300026","article-title":"Inhibition of human gastric lipase secretion by glucagon-like peptide-1","volume":"43","author":"Wojdemann","year":"1998","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejphar.2012.09.024_bib51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejphar.2006.08.011","article-title":"E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-o ne tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitor","volume":"548","author":"Yasuda","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.09.024_bib53","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1016\/j.bmc.2012.08.012","volume":"20","author":"Yoshida","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2012.09.024_bib52","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299912007984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299912007984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T09:23:00Z","timestamp":1542705780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299912007984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":53,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0014299912007984"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2012.09.024","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}